PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v3i1.809Articlehttps://artdesignp.com/journal/PAR/3/1/10.26689/par.v3i1.809CuiYanyan2019312019-08-28Objective: To analyze the efficacy of capecitabine (referred to as Cap) single-agent maintenance therapy in the advanced breast cancer. Methods: The subjects of the study were 50 patients with advanced breast cancer who were admitted to the hospital between March 2016 and March 2019. They were divided into groups A and B with 25 cases each. The subjects of these two groups were treated with Cap and conventional method, respectively to compare the efficacy. Results: The efficacy of group A was 96.0% compared to that of group B was 76.0%. The complication rate of group A was 12.0% compared to that of group B was 40.0% (P < 0.05). Conclusion: The patients with advanced breast cancer who received Cap maintenance therapy were benefited from better curative effect and controllable complications, which has high promotion value.